OTCMKTS:IPCIF

Intellipharmaceutics International (IPCIF) Stock Price, News & Analysis

Intellipharmaceutics International logo

About Intellipharmaceutics International Stock (OTCMKTS:IPCIF)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
12,042 shs
Market Capitalization
$4.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Intellipharmaceutics International Inc. is a Canadian pharmaceutical company focused on developing oral drug products, particularly formulations designed to control or target the release of medication. Its work has included generic and specialty pharmaceutical candidates using proprietary technologies such as IntelliMatrix, IntelliMelt and IntelliGI.

The company has developed formulations for a range of therapeutic areas, including central nervous system disorders, cardiovascular conditions and pain. Its development activities have included pursuing regulatory approvals for products in the United States and Canada.

Founded in 1998 and based in Toronto, Intellipharmaceutics was co-founded by pharmaceutical scientist Isa Odidi, who served as a senior company leader. The company’s work has centered on formulation development and drug-delivery technology rather than operating as a broad-based commercial drug manufacturer.

AI Generated. May Contain Errors.

Receive IPCIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IPCIF Stock News Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More Headlines

IPCIF Stock Analysis - Frequently Asked Questions

Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) released its quarterly earnings data on Monday, July, 16th. The company reported ($0.70) EPS for the quarter, meeting analysts' consensus estimates of ($0.70). The firm earned $580 thousand during the quarter, compared to the consensus estimate of $900 thousand.

Intellipharmaceutics International's stock reverse split on Friday, September 14th 2018.The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intellipharmaceutics International investors own include Micron Technology (MU), Eyepoint Pharmaceuticals (EYPT), Aurinia Pharmaceuticals (AUPH), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Chesapeake Energy (CHKAQ) and BioLineRx (BLRX).

Company Calendar

Today
11/19/2026
Fiscal Year End
11/30/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:IPCIF
CIK
1474835
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$660 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.32) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
33,093,000
Free Float
32,511,000
Market Cap
$4.96 million
Optionable
Not Optionable
Beta
1.53
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (OTCMKTS:IPCIF) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners